checkAd

     142  0 Kommentare ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment - Seite 3

    Contacts:
    Susan M. Kanaya
    Executive Vice President,
    Chief Financial and Administrative Officer
    investor@chemocentryx.com

    Media:
    Stephanie Tomei
    408.234.1279
    media@chemocentryx.com

    Lesen Sie auch

    Investors:
    William Slattery, Jr., Burns McClellan
    212.213.0006 
    bslattery@burnsmc.com 



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment - Seite 3 - Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1 interaction and signaling in vitro and potent …